GL1X · GenesisL1 explorer

Research workbench

Crystal structure of human MYT1 kinase domain (untreated) in complex with saracatinib

Analyse Crystal structure of human MYT1 kinase domain (untreated) in complex with… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
5VCX
Type
protein
Length
287 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Membrane-associated tyrosine- and threonine-specific CDC2- inhibitory kinase
EC
2.7.11.1
UniProt
Q99640
Ligands
H8H
Pockets
2 · best druggability 0.71

Structure

x-ray diffraction · 1 distinct chain · 33% helix, 20% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AMembrane-associated tyrosine- and threonine-specific CDC2- inhibitory kinase (EC 2.7.11.1)protein28733% helix, 20% strandQ99640

Ligands and binding sites

  • H8H · N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine · ligand · chains A
  • EDO · 1,2-ethanediol · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15780.710.7956H8H, EDO
2660.330.7617empty

Compared structures

  • 5VCX · Crystal structure of human MYT1 kinase domain (untreated) in complex with saracatinib · the same entry in another collection · chain A against A, TM-score 1.00
  • Q99640 · AlphaFold monomer V2.0 prediction for membrane-associated tyrosine- and… · a predicted model of the same protein · chain A against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.